ID: MRFR/HC/7284-HCR | February 2023 | Region: Global | 90 Pages
Targeted Liposomes Drug Delivery Market is expected to reach a value of USD 4702.49 Million register at a CAGR of 9.80% during the forecast 2022-2030
$4702.49 Million
9.80%
North America
2022-2030
Market Forecast
The Targeted Liposomes Drug Delivery Market is anticipated to reach USD 4702.49 Million by 2030 at 9.80% CAGR during the forecast period 2022-2030.
Market Synopsis
Lately, the targeted liposomes drug delivery systems have played a significant role in the formulation of a potent drug to improve therapeutic outcomes in patients. The liposome formulations are targeted to reduce the toxicity and surge the accumulation at the target site. This mode of drug delivery lends high efficacy for the administration of various drug classes, such as anti-fungal, anti-viral, antimicrobial, anti-tubercular drugs, vaccines, and gene therapeutics. The increasing occurrences of chronic and life-threatening diseases push the demand for precise drug delivery mechanisms. This pushes the key players to come up with several innovations in the industry to withstand competitive pressure.
Market Influencer
The growing understanding of the heterogeneity of patients, the large variety of individual requirements within each given therapy, the rising awareness regarding the importance of a controlled release distribution, and the availability of the drug in the body, are some factors that are positively contributing to the growth of the Targeted Liposomes Drug Delivery Market.
Market Drivers
New product launches in recent years
Market Restraints
Segmentation
Targeted Liposomes Drug Delivery Market By Type
Targeted Liposomes Drug Delivery Market By Application
Targeted Liposomes Drug Delivery Market By Region
Key Players
Report Attribute/Metric | Details |
---|---|
Market Size | 2030: USD 4702.49 Million |
CAGR | 9.80% (2022-2030) |
Base Year | 2021 |
Forecast Period | 2022-2030 |
Historical Data | 2021 |
Forecast Units | Value (USD Million) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Type and Application |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Catalent (US), Pacira Pharmaceuticals, Inc. (US), Baxter (US), Lonza (Switzerland), Evonik (Germany), Merck KGaA (Germany), Fareva (France), Vetter (Germany), Polymun Scientific Immunbiologische Forschung GmbH (Austria), Recipharm AB (Sweden) and Dalton Pharma Services (Canada) |
Key Market Opportunities | The targeted liposomes drug delivery systems have played a significant role in the formulation of a potent drug to improve therapeutic outcomes in patients |
Key Market Drivers |
|
Global targeted liposomes drug delivery market is expected to record a substantial market valuation of USD 4702.49 Million by 2030.
Global targeted liposomes drug delivery market is projected to register a moderate 9.80% CAGR in the forecast period.
The Liposomal Doxorubicin segment is touted to observe substantial demand over the review period.
The fungal infection therapy segment is slated to mature as the fastest-growing segment.
A few eminent market players functioning in the global targeted liposomes drug delivery market are Baxter (US), Lonza (Switzerland), Evonik (Germany), among others.